Rockwell Medical (RMTI) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 07, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	000-23661
Entity Registrant Name	ROCKWELL MEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3317208
Entity Address, Address Line One	411 Hackensack Avenue, Suite 501,
Entity Address, City or Town	Hackensack,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07601
City Area Code	248
Local Phone Number	960-9009
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	RMTI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding (in shares)		70,297,814
Entity Central Index Key	0001041024
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2020	Dec. 31, 2019
ASSETS
Cash and Cash Equivalents	$ 26,697,063	$ 11,794,526
Investments Available-for-Sale	13,258,197	14,250,176
Accounts Receivable, net	3,565,292	4,202,725
Inventory, net	4,557,177	3,646,906
Prepaid and Other Current Assets	3,458,104	2,979,504
Total Current Assets	51,535,833	36,873,837
Property and Equipment, net	2,306,462	2,433,405
Inventory, Non-Current	821,000	441,000
Right of Use Assets, net	2,440,115	3,212,530
Goodwill	920,745	920,745
Other Non-Current Assets	560,588	434,935
Total Assets	58,584,743	44,316,452
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	3,313,240	3,018,424
Accrued Liabilities	4,437,080	4,517,732
Settlement Payable	0	104,000
Lease Liability - Current	1,342,228	1,493,394
Deferred License Revenue - Current	2,174,626	2,233,640
Insurance Financing Note Payable	0	763,422
Customer Deposits	38,273	55,100
Other Current Liability - Related Party	189,600	187,849
Total Current Liabilities	11,495,047	12,373,561
Lease Liability - Long-Term	1,204,210	1,780,626
Term Loan, Net of Issuance Costs	20,764,213	0
Deferred License Revenue - Long-Term	8,909,703	9,842,762
Total Liabilities	42,373,173	23,996,949
Commitments and Contingencies (See Note 14)
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019	0	0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 70,156,922 and 65,378,890 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	7,017	6,538
Additional Paid-in Capital	337,551,385	326,777,250
Accumulated Deficit	(321,392,548)	(306,516,265)
Accumulated Other Comprehensive Income	45,716	51,980
Total Stockholders’ Equity	16,211,570	20,319,503
Total Liabilities and Stockholders’ Equity	$ 58,584,743	$ 44,316,452

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized (in shares)	2,000,000	2,000,000
Preferred shares, shares issued (in shares)	0	0
Preferred shares, shares outstanding (in shares)	0	0
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	170,000,000	170,000,000
Common Shares, shares issued (in shares)	70,156,922	65,378,890
Common Shares, shares outstanding (in shares)	70,156,922	65,378,890

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net Sales	$ 15,895,971	$ 14,845,788	$ 31,752,510	$ 30,405,227
Cost of Sales	15,015,404	14,112,639	29,759,017	28,661,686
Gross Profit	880,567	733,149	1,993,493	1,743,541
Selling and Marketing	1,996,595	2,218,997	4,069,393	5,321,375
General and Administrative	2,871,013	5,496,670	8,144,445	11,717,169
Settlement Expense	0	430,000	0	430,000
Research and Product Development	1,616,393	2,958,276	3,437,881	3,455,552
Operating Loss	(5,603,434)	(10,370,794)	(13,658,226)	(19,180,555)
Other Income (Expense)
Realized Gain on Investments	2,065	4,135	3,994	18,023
Warrant Modification Expense	(837,322)	0	(837,322)	0
Interest Expense	(520,604)	0	(622,556)	0
Interest Income	66,750	74,476	237,827	192,002
Total Other Income	(1,289,111)	78,611	(1,218,057)	210,025
Net Loss	$ (6,892,545)	$ (10,292,183)	$ (14,876,283)	$ (18,970,530)
Basic and Diluted Net Loss per Share (in dollars per share)	$ (0.10)	$ (0.18)	$ (0.22)	$ (0.33)
Basic and Diluted Weighted Average Shares Outstanding (in shares)	69,428,574	58,216,066	68,473,407	57,660,947

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net Loss	$ (6,892,545)	$ (10,292,183)	$ (14,876,283)	$ (18,970,530)
Unrealized Loss on Available-for-Sale Debt Instrument Investments	(5,701)	11,426	(12,411)	4,265
Foreign Currency Translation Adjustments	536	236	6,147	144
Comprehensive Loss	$ (6,897,710)	$ (10,280,521)	$ (14,882,547)	$ (18,966,121)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME	Bought Deal	Bought DealCOMMON STOCK	Bought DealADDITIONAL PAID-IN CAPITAL	Public offering	Public offeringCOMMON STOCK	Public offeringADDITIONAL PAID-IN CAPITAL	At-the-market offering	At-the-market offeringCOMMON STOCK	At-the-market offeringADDITIONAL PAID-IN CAPITAL
Beginning balance (in shares) at Dec. 31, 2018		57,034,154
Beginning balance at Dec. 31, 2018	$ 27,276,874	$ 5,703	$ 299,596,257	$ (272,388,234)	$ 63,148
Increase (Decrease) in Shareholders' Equity
Net Loss	(8,678,347)			(8,678,347)
Unrealized Loss on Available-for-Sale Investments	(7,161)				(7,161)
Foreign Currency Translation Adjustments	(92)				(92)
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)		64,173
Vesting of Restricted Stock Units Issued, net of taxes withheld	(95,429)	$ 7	(95,436)
Exercise of Employee Stock Options, Net of Tax (in shares)		30,000
Exercise of Employee Stock Options, Net of Tax	147,900	$ 3	147,897
Stock-based Compensation	1,517,302		1,517,302
End balance (in shares) at Mar. 31, 2019		57,128,327
End balance at Mar. 31, 2019	20,161,047	$ 5,713	301,166,020	(281,066,581)	55,895
Beginning balance (in shares) at Dec. 31, 2018		57,034,154
Beginning balance at Dec. 31, 2018	27,276,874	$ 5,703	299,596,257	(272,388,234)	63,148
Increase (Decrease) in Shareholders' Equity
Net Loss	(18,970,530)
Unrealized Loss on Available-for-Sale Investments	4,265
Foreign Currency Translation Adjustments	144
End balance (in shares) at Jun. 30, 2019		63,398,704
End balance at Jun. 30, 2019	29,591,739	$ 6,340	320,876,606	(291,358,764)	67,557
Beginning balance (in shares) at Dec. 31, 2018		57,034,154
Beginning balance at Dec. 31, 2018	$ 27,276,874	$ 5,703	299,596,257	(272,388,234)	63,148
Increase (Decrease) in Shareholders' Equity
Issuance of common stock, net of offering costs (in shares)	1,840,443
End balance (in shares) at Dec. 31, 2019	65,378,890	65,378,890
End balance at Dec. 31, 2019	$ 20,319,503	$ 6,538	326,777,250	(306,516,265)	51,980
Beginning balance (in shares) at Mar. 31, 2019		57,128,327
Beginning balance at Mar. 31, 2019	20,161,047	$ 5,713	301,166,020	(281,066,581)	55,895
Increase (Decrease) in Shareholders' Equity
Net Loss	(10,292,183)			(10,292,183)
Unrealized Loss on Available-for-Sale Investments	11,426				11,426
Foreign Currency Translation Adjustments	236				236
Issuance of common stock, net of offering costs (in shares)										5,833,334			437,043
Issuance of common stock, net of offering costs									$ 16,120,679	$ 583	$ 16,120,096	$ 2,089,208	$ 44	$ 2,089,164
Stock-based Compensation	1,501,326		1,501,326
End balance (in shares) at Jun. 30, 2019		63,398,704
End balance at Jun. 30, 2019	$ 29,591,739	$ 6,340	320,876,606	(291,358,764)	67,557
Beginning balance (in shares) at Dec. 31, 2019	65,378,890	65,378,890
Beginning balance at Dec. 31, 2019	$ 20,319,503	$ 6,538	326,777,250	(306,516,265)	51,980
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,983,738)			(7,983,738)
Unrealized Loss on Available-for-Sale Investments	(6,710)				(6,710)
Foreign Currency Translation Adjustments	5,611				5,611
Issuance of common stock, net of offering costs (in shares)							3,670,212
Issuance of common stock, net of offering costs						$ 8,003,957	$ 367	$ 8,003,590
Issuance of Warrants related to Debt Financing	500,736		500,736
Stock-based Compensation	934,846		934,846
End balance (in shares) at Mar. 31, 2020		69,049,102
End balance at Mar. 31, 2020	$ 21,774,205	$ 6,905	336,216,422	(314,500,003)	50,881
Beginning balance (in shares) at Dec. 31, 2019	65,378,890	65,378,890
Beginning balance at Dec. 31, 2019	$ 20,319,503	$ 6,538	326,777,250	(306,516,265)	51,980
Increase (Decrease) in Shareholders' Equity
Net Loss	(14,876,283)
Unrealized Loss on Available-for-Sale Investments	(12,411)
Foreign Currency Translation Adjustments	$ 6,147
Issuance of common stock, net of offering costs (in shares)	987,716
End balance (in shares) at Jun. 30, 2020	70,156,922	70,156,922
End balance at Jun. 30, 2020	$ 16,211,570	$ 7,017	337,551,385	(321,392,548)	45,716
Beginning balance (in shares) at Mar. 31, 2020		69,049,102
Beginning balance at Mar. 31, 2020	21,774,205	$ 6,905	336,216,422	(314,500,003)	50,881
Increase (Decrease) in Shareholders' Equity
Net Loss	(6,892,545)			(6,892,545)
Unrealized Loss on Available-for-Sale Investments	(5,701)				(5,701)
Foreign Currency Translation Adjustments	536				536
Issuance of common stock, net of offering costs (in shares)										987,716
Issuance of common stock, net of offering costs									$ 1,977,630	$ 99	$ 1,977,531
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)		120,104
Vesting of Restricted Stock Units Issued, net of taxes withheld	(18,863)	$ 13	(18,876)
Warrant Modification Expense	837,322		837,322
Stock-based Compensation	$ (1,461,014)		(1,461,014)
End balance (in shares) at Jun. 30, 2020	70,156,922	70,156,922
End balance at Jun. 30, 2020	$ 16,211,570	$ 7,017	$ 337,551,385	$ (321,392,548)	$ 45,716

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Loss	$ (6,892,545)	$ (7,983,738)	$ (10,292,183)	$ (8,678,347)	$ (14,876,283)	$ (18,970,530)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization					407,680	380,372
Stock-based Compensation					(526,168)	3,018,628
Warrant Modification Expense	837,322		0		837,322	0
Increase in Inventory Reserves					12,000	192,000
Amortization of Right of Use Asset					748,160	975,947
Amortization of Debt Financing Costs and Accretion of Debt Discount					107,527	0
Loss (Gain) on Disposal of Assets					6,048	(300)
Realized (Gain) on Sale of Investments Available-for-Sale					(3,996)	(18,023)
Foreign Currency Translation Adjustment					6,147	144
Changes in Assets and Liabilities:
Decrease in Accounts Receivable, net					637,432	1,590,656
Decrease in Insurance Receivable					0	371,217
(Increase) Decrease in Inventory					(1,302,270)	66,141
(Increase) Decrease in Prepaid and Other Assets					(607,574)	125,750
Increase (Decrease) in Accounts Payable					294,816	(426,772)
Increase (Decrease) in Settlement Payable					(104,000)	13,332
Decrease in Lease Liability					(703,327)	(977,636)
Decrease in Other Liabilities					(95,728)	(992,909)
Decrease in Deferred License Revenue					(992,073)	(1,126,434)
Changes in Assets and Liabilities					(2,872,724)	(1,356,655)
Cash Used In Operating Activities					(16,154,287)	(15,778,417)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale					(16,513,592)	(21,774,410)
Sale of Investments Available-for-Sale					17,497,153	18,798,678
Purchase of Equipment					(283,462)	(305,030)
Purchase of Research and Development Licenses (Related Party)					0	(500,000)
Cash Provided By (Used In) Investing Activities					700,099	(3,780,762)
Cash Flows From Financing Activities:
Proceeds from Term Loan					22,500,000	0
Debt Issuance Costs					(1,342,578)	0
Payments on Short Term Note Payable					(763,421)	0
Proceeds from the Issuance of Common Stock / Public Offering					2,034,073		$ 5,383,079
Offering Costs from the Issuance of Common Stock / Public Offering					(56,443)		(309,479)
Proceeds from the Exercise of Employee Stock Options					0	147,900
Repurchase of Common Stock to Pay Employee Withholding Taxes					(18,863)	(95,429)
Cash Provided By Financing Activities					30,356,725	18,262,358
Increase (Decrease) In Cash and Cash Equivalents					14,902,537	(1,296,821)
Cash and cash equivalents At Beginning Of Period		$ 11,794,526		$ 22,713,980	11,794,526	22,713,980	22,713,980
Cash and cash equivalents At End Of Period	$ 26,697,063		$ 21,417,159		26,697,063	21,417,159	$ 11,794,526
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest					409,931	0
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale					(12,411)	4,265
Insurance Financing Note Payable					0	1,908,554
Fair Value of Warrants issued related to Debt Financing					500,736	0
Public offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					8,147,871	17,500,002
Offering Costs from the Issuance of Common Stock / Public Offering					(143,914)	(1,379,323)
At-the-market offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					2,034,073	2,296,235
Offering Costs from the Issuance of Common Stock / Public Offering					$ (56,443)	$ (207,027)

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Rockwell Medical, Inc. and subsidiaries (collectively, “we”, “our”, “us”, or the “Company”), is a biopharmaceutical company dedicated to improving outcomes for patients with iron deficiency and iron-deficiency anemia, with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate citrate (“FPC”) therapeutic platform. The first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients. We initiated commercial sales of Triferic Dialysate, during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients’ lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency. Triferic® is a registered trademark of Rockwell Medical, Inc.

Liquidity and Capital Resources

Liquidity and Capital Resources	6 Months Ended
	Jun. 30, 2020
Liquidity and Capital Resources
Liquidity and Capital Resources	Liquidity and Capital Resources As of June 30, 2020 , the Company had approximately $26.7 million of cash and cash equivalents, $13.3 million of investments available-for-sale, working capital of $40.0 million and an accumulated deficit of $321.4 million . Net cash used in operating activities for the six months ended June 30, 2020 was approximately $16.2 million . Management evaluated the Company’s ability to continue as going concern for at least the next 12 months from the filing of this report. Based on the currently available working capital, capital raise and debt financing described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report. In February 2020, the Company sold 3,670,212 shares of its common stock for proceeds of $8.0 million , net of issuance costs. On March 16, 2020, the Company closed a debt financing transaction with net proceeds at closing of approximately $21.2 million , net of fees and expenses (See Note 15 for further detail). During the six months ended June 30, 2020, the Company sold 987,716 shares of its common stock as part of its sales agreement with Cantor Fitzgerald & Co. for proceeds of $2.0 million , net of issuance costs. Approximately $32.6 million remains available for sale under this facility. See Note 10 for further detail. The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the continued commercialization of Triferic Dialysate and Triferic AVNU, executing plans for enhancing its medical capabilities, generating additional data for Triferic and developing Triferic for new therapeutic indications. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all. The COVID-19 pandemic and resulting global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. As noted above, we intend to initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch. Quarantines, shelter-in-place, executive and similar government orders may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending on the severity of the impact on our sales and marketing efforts, the timing of our commercial launch of Triferic AVNU could be adjusted into the first quarter of 2021. The COVID-19 pandemic and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (“U.S.”) of America (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet at June 30, 2020 , condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 , condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 , and condensed consolidated statement of changes in shareholder’s equity for the three and six months ended June 30, 2020 and 2019 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020 or for any future interim period. The condensed consolidated balance sheet at December 31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as filed with the SEC on Form 10-K on March 17, 2020. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of June 30, 2020 2019 Options to purchase common stock 6,225,562 8,187,161 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 503,395 1,658,205 Warrants to purchase common stock 3,248,054 2,770,781 10,123,811 12,762,947 Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: • Step 1: Identify the contract with the customer • Step 2: Identify the performance obligations in the contract • Step 3: Determine the transaction price • Step 4: Allocate the transaction price to the performance obligations in the contract • Step 5: Recognize revenue when the company satisfies a performance obligation Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer. Nature of goods and services The following is a description of principal activities from which the Company generates its revenue. Product sales – The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach. Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer. The Company received upfront fees under three distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”) and amounts to be received from Sun Pharmaceutical Industries Ltd. ("Sun Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China and India, respectively, to determine that regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”), are recognized as revenue at the point in time that the estimated product sales under the agreement occur. For the business under the Company’s distribution agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days , while distributor payment terms average 45 days . Disaggregation of revenue Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 182 $ 182 $ — $ 381 $ 381 $ — License Fee – Over time 56 — 56 112 — 112 Total Drug Products 238 182 56 493 381 112 Concentrate Products Product Sales – Point-in-time 15,168 13,319 1,849 30,280 26,826 3,454 License Fee – Over time 490 490 — 980 980 — Total Concentrate Products 15,658 13,809 1,849 31,260 27,806 3,454 Net Revenue $ 15,896 $ 13,991 $ 1,905 $ 31,753 $ 28,187 $ 3,566 In thousands of US dollars ($) Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 15 $ 15 $ — $ 15 $ 15 $ — License Fee – Over time $ 68 $ — 68 136 — 136 Total Drug Products 83 15 68 151 15 136 Concentrate Products Product Sales – Point-in-time 14,268 12,822 1,446 29,264 25,746 3,518 License Fee – Over time 495 495 — 990 990 — Total Concentrate Products 14,763 13,317 1,446 30,254 26,736 3,518 Net Revenue $ 14,846 $ 13,332 $ 1,514 $ 30,405 $ 26,751 $ 3,654 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of US dollars ($) June 30, 2020 December 31, 2019 Receivables, which are included in "Trade and other receivables" $ 3,565 $ 4,203 Contract liabilities $ 11,084 $ 12,076 There were no material losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 2020 and 2019 . For the three and six months ended June 30, 2020 and June 30, 2019 , the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of June 30, 2020 and December 31, 2019 . The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of June 30, 2020 or December 31, 2019 . The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products Transaction price allocated to remaining performance obligations For the three and six months ended June 30, 2020 , revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $11.1 million as of June 30, 2020 . The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled performance obligations related to the Baxter Agreement are product sales of $8.2 million as of June 30, 2020, which is being amortized ratably through expiration of the Baxter Agreement on October 2, 2024.

Investments - Available-for-Sal

Investments - Available-for-Sale	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Investments - Available-for-Sale	Investments - Available-for-Sale Investments available-for-sale consisted of the following as of June 30, 2020 and December 31, 2019 : June 30, 2020 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value Available-for-Sale Securities Bonds $ 13,172,049 $ 14,468 $ (447 ) $ 72,127 $ 13,258,197 December 31, 2019 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 14,238,161 $ 13,321 $ (1,306 ) $ — $ 14,250,176 The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements. As of June 30, 2020 and December 31, 2019 , the amortized cost and estimated fair value of our available-for-sale securities were due within one year.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventory	Inventory Components of inventory, net of reserves, as of June 30, 2020 and December 31, 2019 are as follows: June 30, December 31, Raw Materials $ 3,041,887 $ 2,471,234 Work in Process 303,545 184,382 Finished Goods 2,032,745 1,432,290 Total $ 5,378,177 $ 4,087,906 As of June 30, 2020 , we classified $0.8 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of June 30, 2020 , we had total Triferic inventory aggregating $3.7 million , against which we had reserved $2.5 million . The $1.2 million net value of Triferic inventory consisted of $0.2 million of Triferic Dialysate finished goods with expiration dates ranging from December 2020 to May 2021, $0.5 million of Triferic API with estimated remaining shelf life extending through 2023, and $0.5 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.

Property And Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of June 30, 2020 and December 31, 2019 , the Company’s property and equipment consisted of the following: June 30, December 31, Leasehold Improvements $ 1,175,986 $ 1,162,328 Machinery and Equipment 4,869,771 4,672,724 Information Technology & Office Equipment 1,822,260 1,810,246 Laboratory Equipment 652,676 653,075 8,520,693 8,298,373 Accumulated Depreciation (6,214,231 ) (5,864,968 ) Property and Equipment, net $ 2,306,462 $ 2,433,405 Depreciation expense for the three months ended June 30, 2020 and 2019 totaled $0.2 million . Depreciation expense for the six months ended June 30, 2020 and 2019 totaled $0.4 million .

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities as of June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Accrued Research & Development Expense $ 268,677 $ 283,407 Accrued Compensation and Benefits 2,032,651 1,018,196 Accrued Legal Expenses 116,578 181,597 Accrued Marketing Expenses 191,797 61,164 Other Accrued Liabilities 1,827,377 2,973,368 Total Accrued Liabilities $ 4,437,080 $ 4,517,732

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Deferred Revenue	Deferred Revenue In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million . The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.0 million for the three and six months ended June 30, 2020 and 2019 , respectively. Deferred revenue related to the Baxter Agreement totaled $8.2 million as of June 30, 2020 and $9.1 million as of December 31, 2019 . If a “Refund Trigger Event” occurs under the Baxter Agreement, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from April 1, 2020 to December 31, 2021, Baxter would be eligible for a 25% refund of the Baxter Agreement’s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020 , Baxter would be eligible for a partial refund of the upfront fee of $5.0 million . In no event does the Baxter Agreement require more than one refund be paid. In 2016 , the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million . The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $53,000 and $0.1 million for the three and six months ended June 30, 2020 and 2019 , respectively. Deferred revenue related to the Wanbang Agreement totaled $2.9 million as of June 30, 2020 and $3.0 million as of December 31, 2019 . On January 14, 2020, we entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in India, and we will supply the product to Sun Pharma. In consideration for the license, we received an upfront fee of $0.1 million , and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate in India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 during the three and six months ended June 30, 2020 , respectively.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity The Company held its annual meeting of stockholders on May 18, 2020 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares of common stock issuable thereunder by 2,900,000 shares (the “Amended 2018 Plan”). Preferred Stock As of June 30, 2020 and December 31, 2019 , there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding. Common Stock As of June 30, 2020 and December 31, 2019 , there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 70,156,922 and 65,378,890 shares issued and outstanding, respectively. Controlled Equity Offering (or "At the Market" Offering) On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019. Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time. During the year ended December 31, 2019, the Company sold 1,840,443 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5,383,079 , at a weighted average selling price of approximately $2.92 . The Company paid $309,479 in commissions and offering fees related to the sale of the common stock. For the six months ended June 30, 2020 , the Company sold 987,716 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $2,034,073 , at a weighted average selling price of approximately $2.06 . The Company paid $56,443 in commissions and offering fees related to the sale of common stock. Approximately $32.6 million remains available for sale under this facility. We are not required to sell any shares at any time during the term of the facility. Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things. Public Offering of Common Stock On February 4, 2020 , the Company entered into an underwriting agreement with Cantor Fitzgerald & Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020 , the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the "Offering"). On February 19, 2020 , the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020 . The Company raised a total of $8.0 million , net of issuance costs of $0.1 million , relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2020 and 2019 as follows: Three Months Ended Six Months Ended 2020 2019 2020 2019 Service-based awards: Restricted stock units $ (4,127 ) $ 427,472 $ 233,987 $ 771,823 Stock option awards 336,513 547,139 776,138 1,199,163 332,386 974,611 1,010,125 1,970,986 Performance-based awards: Restricted stock units (1,196,713 ) 402,814 (1,025,502 ) 801,202 Stock option awards (596,687 ) 123,901 (510,791 ) 246,440 (1,793,400 ) 526,715 (1,536,293 ) 1,047,642 Total $ (1,461,014 ) $ 1,501,326 $ (526,168 ) $ 3,018,628 Restricted Stock A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2020 146,800 $ 5.70 Unvested at June 30, 2020 146,800 $ 5.70 A summary of the Company’s restricted stock awards during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 146,800 $ 5.70 Unvested at June 30, 2019 146,800 $ 5.70 The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months . As of June 30, 2020 , unvested restricted stock awards of 146,800 were related to performance-based awards. Service-Based Restricted Stock Units A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 463,786 $ 4.26 Granted 188,904 2.09 Vested (128,460 ) 4.30 Forfeited (104,168 ) 4.66 Unvested at June 30, 2020 420,062 $ 3.27 A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 472,959 $ 4.32 Granted 199,938 4.45 Forfeited (3,650 ) 4.81 Unvested at June 30, 2019 669,247 $ 4.36 The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years . Stock-based compensation expense of nil and $0.2 million was recognized during the three and six months ended June 30, 2020 , respectively. Stock-based compensation expense of $0.4 million and $0.8 million was recognized during the three and six months ended June 30, 2019 , respectively. As of June 30, 2020 , the unrecognized stock-based compensation expense was $0.6 million , which is expected to be recognized over an estimated weighted average remaining term of 1 year . Included in the forfeited service-based restricted stock units are 96,541 units related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $0.2 million . Performance-Based Restricted Stock Units A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 988,958 $ 4.48 Forfeited (905,625) 4.61 Unvested at June 30, 2020 83,333 $ 3.09 A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 988,958 $ 4.48 Unvested at June 30, 2019 988,958 $ 4.48 Stock-based compensation expense recognized for performance-based restricted stock units was ($1.2) million and ($1.0) million during the three and six months ended June 30, 2020 and $0.4 million and $0.8 million for the three and six months ended June 30, 2019 , respectively. As of June 30, 2020 , the unrecognized stock-based compensation expense related to performance-based restricted stock units was $0.1 million , which is expected to be recognized over an estimated weighted average remaining term of 2 years . The forfeited performance-based restricted stock awards of 905,625 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $1.3 million . Service-Based Stock Options The fair value of the service-based stock options granted for the six months ended June 30, 2020 were based on the following assumptions: June 30, Exercise price $1.77 - $2.45 Expected stock price volatility 68.2% - 74.4% Risk-free interest rate 0.35% - 1.65% Term (years) 5.5 -6.5 A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2020 8,210,024 $ 7.06 5.1 $ 107,150 Granted 1,610,344 2.24 5.9 — Forfeited (211,471 ) 4.41 — — Expired (3,983,335 ) 8.30 — — Outstanding at June 30, 2020 5,625,562 $ 4.90 6.7 $ 1,100 Exercisable at June 30, 2020 2,809,954 $ 7.09 4.3 $ — A summary of the Company’s service-based stock option activity for the six months ended June 30, 2019 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2019 7,856,480 $ 7.50 5.2 $ — Granted 523,105 4.33 9.7 — Exercised (30,000 ) 4.93 — — Forfeited (550,549 ) 6.67 — — Outstanding at June 30 7,799,036 $ 7.36 5.4 $ 2,500 Exercisable at June 30, 2019 6,183,193 $ 8.16 4.3 $ — The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price. During the six months ended June 30, 2020 , the Company granted stock options to purchase up to 1,610,344 shares of common stock to certain employees. During the six months ended June 30, 2020 , 211,471 shares were forfeited. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.8 million for the three and six months ended June 30, 2020 , respectively. Stock-based compensation expense recognized for service-based stock options was $0.5 million and $1.2 million for the three and six months ended June 30, 2019 , respectively. As of June 30, 2020 , total stock-based compensation expense related to unvested options not yet recognized totaled approximately $3.1 million , which is expected to be recognized over an estimated weighted average remaining term of 1.4 years . Included in the forfeited service-based stock options are 129,375 unvested options related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $0.2 million . Included in the expired service-based stock options are 3,783,335 options related to the settlement with the former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. See Note 14 for further details. Performance-Based Stock Options A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2020 388,125 $ 4.70 Granted 600,000 2.45 Forfeited (388,125 ) 4.70 Outstanding at June 30, 2020 600,000 $ 2.45 Exercisable at June 30, 2020 — $ — A summary of the performance-based stock options for the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2019 388,125 $ 4.70 Outstanding at June 30, 2019 388,125 $ 4.70 Exercisable at June 30, 2019 — $ — Stock-based compensation expense recognized for performance-based stock options was ($0.6) million and ($0.5) million for the three and six months ended June 30, 2020 . Stock-based compensation expense recognized for performance-based stock options was $0.1 million and $0.2 million during the three and six months ended June 30, 2019 . As of June 30, 2020 , the unrecognized stock-based compensation expense related to unvested performance-based stock options was $0.1 million . The forfeited unvested performance-based stock options of 388,125 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited options reduced stock-based compensation expense by $0.7 million .

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Product License Agreements The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company recorded $1.1 million as Research and Development Expense - License Acquired (Related Party) for the twelve months ended December 31, 2018 . The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019 . As of June 30, 2020 , and December 31, 2019 , the Company accrued $27,500 and $0.1 million , respectively, as a related party payable on the condensed consolidated balance sheet. In addition, the Company accrued $0.2 million relating to certain IP reimbursement expenses as a related party payable on the condensed consolidated balance sheet. Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, Business Combinations (Topic 805) , Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company’s statement of operations for the year ended December 31, 2018 . In addition, because the potential milestone payments are not yet considered probable, no milestone payments have been accrued at June 30, 2020 .

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Leases We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to five years . We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021. In addition, we executed a lease for 4,100 square feet of office space in Hackensack, New Jersey with a lease term beginning on April 1, 2019 and expiring on July 1, 2024. At June 30, 2020 , the Company had operating lease liabilities of $2.5 million and right-of-use assets of $2.4 million , which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating leases Operating lease cost $ 403,077 $ 554,921 $ 845,905 $ 1,089,888 Variable lease cost 122,865 78,237 312,149 168,081 Operating lease expense 525,942 633,158 1,158,054 1,257,969 Short-term lease rent expense 4,157 4,122 8,313 8,313 Total rent expense $ 530,099 $ 637,280 $ 1,166,367 $ 1,266,282 Other information Operating cash flows from operating leases $ 410,092 $ 514,116 $ 854,785 $ 1,038,081 Right of use assets exchanged for operating lease liabilities $ — $ 821,195 $ — $ 4,305,428 Weighted-average remaining lease term – operating leases 2.4 2.6 2.4 2.6 Weighted-average discount rate – operating leases 6.8 % 6.8 % 6.8 % 6.8 % Future minimum rental payments under operating lease agreements are as follows: Year ending December 31, 2020 (remaining) $ 780,038 Year ending December 31, 2021 1,054,873 Year ending December 31, 2022 591,925 Year ending December 31, 2023 234,327 Year ending December 31, 2024 97,423 Total $ 2,758,586 Less present value discount (212,148 ) Operating lease liabilities $ 2,546,438

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Demand Notice In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015. The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested $3.0 million in penalties, plus payment of the cost for certain raw materials. No lawsuit was filed. While the Company believed it had several defenses to the supplier's claim, the Company and the supplier negotiated an amicable resolution of the dispute. On July 31, 2020, the Company and the supplier entered into a settlement agreement, which released the Company from any penalties relating to annual minimums under the 2015 agreement, established new minimums under an amended supply agreement and required the Company to pay for certain raw materials with 50% of the cost to be paid upon execution of the settlement agreement and the remaining 50% to be paid no later than December 31, 2020. Litigation SEC Investigation As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2019 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement status for Triferic Dialysate, the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information. Shareholder Class Action Lawsuits On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company’s drug, Triferic, to quality for separate reimbursement status by the CMS. On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company’s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company’s proposal for separate reimbursement for Triferic; misstated reserves in the Company’s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company’s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company’s business were materially false and misleading. On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the Ah Kit Too v. Rockwell securities class action with the Spock v. Rockwell securities class action. On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel. On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company’s securities between November 8, 2017 and June 26, 2018. On February 18, 2019, the Company answered the consolidated amended complaint. On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action. Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the “Settlement Amount") in exchange for a full release of all liability as to all defendants. This resulted in a settlement expense of approximately $0.4 million for the year ended December 31, 2019. Of the Settlement Amount, the Company contributed approximately $0.1 million , which represented the remaining retention amount under the Company’s director and officer liability insurance policy as of June 30, 2020 . The remainder of the settlement amount has been funded by the Company’s director and officer insurance policy. The settlement was approved by the court on February 26, 2020. Shareholder Derivative Actions Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the “Derivative Complaints”) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company’s current and former directors (the “Individual Defendants”). The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment. The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls. The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors’ trading activities, restitution, and attorneys’ fees. The cases have been consolidated and the parties are in advanced settlement discussions. If a settlement is not reached, the Defendants anticipate filing motions to dismiss. The Company tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. On May 18, 2020, the Company, the Individual Defendants and the Plaintiffs (the "Settling Parties") entered into a formal Stipulation of Settlement, which memorializes the terms of the Settling Parties' settlement of the Derivative Complaints. On June 2, 2020, the court issued an order preliminarily approving the settlement. A hearing is set for August 10, 2020 to determine if the court should issue a final order approving the final settlement. The Company has exhausted self-insured retention under the above insurance policies. The Company’s director and officer insurance company has funded the settlement amount on behalf of the Company. Termination of our former CEO and CFO On August 7, 2018, the Company entered into a confidential settlement agreement and mutual release with Robert Chioini, its former Chief Executive Officer, Thomas Klema, its former Chief Financial Officer and a former and then current director. For more details see Note 15 in the Company’s Annual Report on Form 10-K filed on March 17, 2020.

Loans and Security Agreement

Loans and Security Agreement	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Loans and Security Agreement	Loan and Security Agreement On March 16, 2020 , Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the FDA approval of the Company’s New Drug Application for Triferic AVNU. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million . The Company is entitled to make interest-only payments for thirty months , or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75% , plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9% . The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended June 30, 2020 and 2019 , interest expense amounted to $0.5 million and nil , respectively. For the six months ended June 30, 2020 and 2019 , interest expense amounted to $0.6 million and nil , respectively. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if the Company draws the second tranche of $5.0 million . As of June 30, 2020 , the Company was in compliance with all the reporting and financial covenants. In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. As of June 30, 2020 , the outstanding balance of the Term Loan was $20.8 million , net of unamortized issuance costs and unaccreted discount of $1.7 million . The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2020 : Principal Payments 2020 $ — 2021 — 2022 2,250,000 2023 9,000,000 2024 9,000,000 2025 2,250,000 $ 22,500,000

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Resignation of Chief Financial Officer On June 5, 2020, Angus Smith, the Company's Chief Financial Officer, notified the Company of his intent to resign from the Company effective July 3, 2020. As a result of Mr. Smith's resignation, certain of his time-based, all of his performance-based and market-based stock awards previously granted to Mr. Smith will be forfeited. Such forfeitures will be reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. The estimated expense the forfeited stock awards is approximately $0.7 million .

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases	Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share	Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of potentially dilutive securities	Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of June 30, 2020 2019 Options to purchase common stock 6,225,562 8,187,161 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 503,395 1,658,205 Warrants to purchase common stock 3,248,054 2,770,781 10,123,811 12,762,947

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 182 $ 182 $ — $ 381 $ 381 $ — License Fee – Over time 56 — 56 112 — 112 Total Drug Products 238 182 56 493 381 112 Concentrate Products Product Sales – Point-in-time 15,168 13,319 1,849 30,280 26,826 3,454 License Fee – Over time 490 490 — 980 980 — Total Concentrate Products 15,658 13,809 1,849 31,260 27,806 3,454 Net Revenue $ 15,896 $ 13,991 $ 1,905 $ 31,753 $ 28,187 $ 3,566 In thousands of US dollars ($) Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 15 $ 15 $ — $ 15 $ 15 $ — License Fee – Over time $ 68 $ — 68 136 — 136 Total Drug Products 83 15 68 151 15 136 Concentrate Products Product Sales – Point-in-time 14,268 12,822 1,446 29,264 25,746 3,518 License Fee – Over time 495 495 — 990 990 — Total Concentrate Products 14,763 13,317 1,446 30,254 26,736 3,518 Net Revenue $ 14,846 $ 13,332 $ 1,514 $ 30,405 $ 26,751 $ 3,654
Contract balances	The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of US dollars ($) June 30, 2020 December 31, 2019 Receivables, which are included in "Trade and other receivables" $ 3,565 $ 4,203 Contract liabilities $ 11,084 $ 12,076

Investments - Available-for-S_2

Investments - Available-for-Sale (Tables)	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Investments available for sale	Investments available-for-sale consisted of the following as of June 30, 2020 and December 31, 2019 : June 30, 2020 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value Available-for-Sale Securities Bonds $ 13,172,049 $ 14,468 $ (447 ) $ 72,127 $ 13,258,197 December 31, 2019 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 14,238,161 $ 13,321 $ (1,306 ) $ — $ 14,250,176

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule components of inventory	Components of inventory, net of reserves, as of June 30, 2020 and December 31, 2019 are as follows: June 30, December 31, Raw Materials $ 3,041,887 $ 2,471,234 Work in Process 303,545 184,382 Finished Goods 2,032,745 1,432,290 Total $ 5,378,177 $ 4,087,906

Property And Equipment (Tables)

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of major classes of property and equipment, stated at cost	As of June 30, 2020 and December 31, 2019 , the Company’s property and equipment consisted of the following: June 30, December 31, Leasehold Improvements $ 1,175,986 $ 1,162,328 Machinery and Equipment 4,869,771 4,672,724 Information Technology & Office Equipment 1,822,260 1,810,246 Laboratory Equipment 652,676 653,075 8,520,693 8,298,373 Accumulated Depreciation (6,214,231 ) (5,864,968 ) Property and Equipment, net $ 2,306,462 $ 2,433,405

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of accrued liabilities	Accrued liabilities as of June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Accrued Research & Development Expense $ 268,677 $ 283,407 Accrued Compensation and Benefits 2,032,651 1,018,196 Accrued Legal Expenses 116,578 181,597 Accrued Marketing Expenses 191,797 61,164 Other Accrued Liabilities 1,827,377 2,973,368 Total Accrued Liabilities $ 4,437,080 $ 4,517,732

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of total stock-based compensation expense	The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2020 and 2019 as follows: Three Months Ended Six Months Ended 2020 2019 2020 2019 Service-based awards: Restricted stock units $ (4,127 ) $ 427,472 $ 233,987 $ 771,823 Stock option awards 336,513 547,139 776,138 1,199,163 332,386 974,611 1,010,125 1,970,986 Performance-based awards: Restricted stock units (1,196,713 ) 402,814 (1,025,502 ) 801,202 Stock option awards (596,687 ) 123,901 (510,791 ) 246,440 (1,793,400 ) 526,715 (1,536,293 ) 1,047,642 Total $ (1,461,014 ) $ 1,501,326 $ (526,168 ) $ 3,018,628
Schedule of restricted stock award	A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2020 146,800 $ 5.70 Unvested at June 30, 2020 146,800 $ 5.70 A summary of the Company’s restricted stock awards during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 146,800 $ 5.70 Unvested at June 30, 2019 146,800 $ 5.70
Restricted stock units - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of restricted stock award	A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 463,786 $ 4.26 Granted 188,904 2.09 Vested (128,460 ) 4.30 Forfeited (104,168 ) 4.66 Unvested at June 30, 2020 420,062 $ 3.27 A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 472,959 $ 4.32 Granted 199,938 4.45 Forfeited (3,650 ) 4.81 Unvested at June 30, 2019 669,247 $ 4.36
Restricted stock units - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of restricted stock award	A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 988,958 $ 4.48 Forfeited (905,625) 4.61 Unvested at June 30, 2020 83,333 $ 3.09 A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 988,958 $ 4.48 Unvested at June 30, 2019 988,958 $ 4.48
Stock option awards - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of stock option assumptions	The fair value of the service-based stock options granted for the six months ended June 30, 2020 were based on the following assumptions: June 30, Exercise price $1.77 - $2.45 Expected stock price volatility 68.2% - 74.4% Risk-free interest rate 0.35% - 1.65% Term (years) 5.5 -6.5
Schedule of stock options activity	A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2020 8,210,024 $ 7.06 5.1 $ 107,150 Granted 1,610,344 2.24 5.9 — Forfeited (211,471 ) 4.41 — — Expired (3,983,335 ) 8.30 — — Outstanding at June 30, 2020 5,625,562 $ 4.90 6.7 $ 1,100 Exercisable at June 30, 2020 2,809,954 $ 7.09 4.3 $ — A summary of the Company’s service-based stock option activity for the six months ended June 30, 2019 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2019 7,856,480 $ 7.50 5.2 $ — Granted 523,105 4.33 9.7 — Exercised (30,000 ) 4.93 — — Forfeited (550,549 ) 6.67 — — Outstanding at June 30 7,799,036 $ 7.36 5.4 $ 2,500 Exercisable at June 30, 2019 6,183,193 $ 8.16 4.3 $ —
Stock option awards - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of stock options activity	A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2020 388,125 $ 4.70 Granted 600,000 2.45 Forfeited (388,125 ) 4.70 Outstanding at June 30, 2020 600,000 $ 2.45 Exercisable at June 30, 2020 — $ — A summary of the performance-based stock options for the six months ended June 30, 2019 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2019 388,125 $ 4.70 Outstanding at June 30, 2019 388,125 $ 4.70 Exercisable at June 30, 2019 — $ —

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Summary of Operating Leases	The following summarizes quantitative information about the Company’s operating leases: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating leases Operating lease cost $ 403,077 $ 554,921 $ 845,905 $ 1,089,888 Variable lease cost 122,865 78,237 312,149 168,081 Operating lease expense 525,942 633,158 1,158,054 1,257,969 Short-term lease rent expense 4,157 4,122 8,313 8,313 Total rent expense $ 530,099 $ 637,280 $ 1,166,367 $ 1,266,282 Other information Operating cash flows from operating leases $ 410,092 $ 514,116 $ 854,785 $ 1,038,081 Right of use assets exchanged for operating lease liabilities $ — $ 821,195 $ — $ 4,305,428 Weighted-average remaining lease term – operating leases 2.4 2.6 2.4 2.6 Weighted-average discount rate – operating leases 6.8 % 6.8 % 6.8 % 6.8 %
Future Minimum Rental Payments Under Operating Leases	Future minimum rental payments under operating lease agreements are as follows: Year ending December 31, 2020 (remaining) $ 780,038 Year ending December 31, 2021 1,054,873 Year ending December 31, 2022 591,925 Year ending December 31, 2023 234,327 Year ending December 31, 2024 97,423 Total $ 2,758,586 Less present value discount (212,148 ) Operating lease liabilities $ 2,546,438

Loans and Security Agreement (T

Loans and Security Agreement (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of principal payments on Term Loan	The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2020 : Principal Payments 2020 $ — 2021 — 2022 2,250,000 2023 9,000,000 2024 9,000,000 2025 2,250,000 $ 22,500,000

Liquidity and Capital Resourc_2

Liquidity and Capital Resources (Details) - USD ($)	Mar. 16, 2020	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Liquidity and Capital Resources
Cash and cash equivalents			$ 26,697,063		$ 11,794,526
Investments available-for-sale			13,258,197		14,250,176
Working capital net			40,000,000
Accumulated deficit			(321,392,548)		(306,516,265)
Net cash used in operating activities			$ (16,154,287)	$ (15,778,417)
Common shares sold (in shares)		3,670,212	987,716
Proceeds from the issuance of common shares		$ 8,000,000	$ 2,034,073		$ 5,383,079
Net draw down proceeds	$ 21,200,000
Remaining amount available for sale			$ 32,600,000

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	10,123,811	12,762,947
Options to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	6,225,562	8,187,161
Unvested restricted stock awards
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	146,800	146,800
Unvested restricted stock units
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	503,395	1,658,205
Warrants to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	3,248,054	2,770,781

Revenue Recognition - Nature of

Revenue Recognition - Nature of Goods and Services (Details)	6 Months Ended
	Jun. 30, 2020agreement
Revenue from Contract with Customer [Abstract]
Number of distribution and license agreements	3
Customers average payment term	30 days
Distributors average payment term	45 days

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Net revenue	$ 15,895,971	$ 14,845,788	$ 31,752,510	$ 30,405,227
Drug Products
Disaggregation of Revenue [Line Items]
Net revenue	238,000	83,000	493,000	151,000
Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	15,658,000	14,763,000	31,260,000	30,254,000
United States
Disaggregation of Revenue [Line Items]
Net revenue	13,991,000	13,332,000	28,187,000	26,751,000
United States | Drug Products
Disaggregation of Revenue [Line Items]
Net revenue	182,000	15,000	381,000	15,000
United States | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	13,809,000	13,317,000	27,806,000	26,736,000
Rest of World
Disaggregation of Revenue [Line Items]
Net revenue	1,905,000	1,514,000	3,566,000	3,654,000
Rest of World | Drug Products
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000	112,000	136,000
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	1,849,000	1,446,000	3,454,000	3,518,000
Point-in-time | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	182,000	15,000	381,000	15,000
Point-in-time | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	15,168,000	14,268,000	30,280,000	29,264,000
Point-in-time | United States | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	182,000	15,000	381,000	15,000
Point-in-time | United States | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	13,319,000	12,822,000	26,826,000	25,746,000
Point-in-time | Rest of World | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	0	0	0	0
Point-in-time | Rest of World | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	1,849,000	1,446,000	3,454,000	3,518,000
Over time | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000	112,000	136,000
Over time | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000	980,000	990,000
Over time | United States | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	0	0	0	0
Over time | United States | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000	980,000	990,000
Over time | Rest of World | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000	112,000	136,000
Over time | Rest of World | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Receivables, which are included in Trade and other receivables	$ 3,565	$ 4,203
Contract liabilities	$ 11,084	$ 12,076

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Revenue Recognition [Line Items]
Impairment losses	$ 0	$ 0	$ 0	$ 0
Contract assets	0		0		$ 0
Revenue performance obligation	11,100,000		11,100,000
Concentrate Products
Revenue Recognition [Line Items]
Reserve for returns	0		0		$ 0
Baxter Healthcare Organization
Revenue Recognition [Line Items]
Revenue performance obligation	$ 8,200,000		$ 8,200,000

Investments - Available-for-S_3

Investments - Available-for-Sale (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Amortized Cost	$ 13,172,049	$ 14,238,161
Unrealized Gain	14,468	13,321
Unrealized Loss	(447)	(1,306)
Accrued Interest Income	72,127	0
Fair Value	$ 13,258,197	$ 14,250,176

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory [Line Items]
Raw Materials	$ 3,041,887	$ 2,471,234
Work in Process	303,545	184,382
Finished Goods	2,032,745	1,432,290
Total	5,378,177	4,087,906
Inventory, noncurrent	821,000	441,000
Inventory, net	4,557,177	$ 3,646,906
Triferic Inventory
Inventory [Line Items]
Raw Materials	500,000
Inventory, noncurrent	800,000
Inventory, gross	3,700,000
Inventory, reserve	2,500,000
Inventory, net	1,200,000
Triferic Dialysate
Inventory [Line Items]
Finished Goods	200,000
Triferic API
Inventory [Line Items]
Inventory, net	$ 500,000

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property and equipment
Gross property and equipment	$ 8,520,693		$ 8,520,693		$ 8,298,373
Accumulated Depreciation	(6,214,231)		(6,214,231)		(5,864,968)
Property and Equipment, net	2,306,462		2,306,462		2,433,405
Depreciation expense	200,000	$ 200,000	400,000	$ 400,000
Leasehold Improvements
Property and equipment
Gross property and equipment	1,175,986		1,175,986		1,162,328
Machinery and Equipment
Property and equipment
Gross property and equipment	4,869,771		4,869,771		4,672,724
Information Technology & Office Equipment
Property and equipment
Gross property and equipment	1,822,260		1,822,260		1,810,246
Laboratory Equipment
Property and equipment
Gross property and equipment	$ 652,676		$ 652,676		$ 653,075

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Research & Development Expense	$ 268,677	$ 283,407
Accrued Compensation and Benefits	2,032,651	1,018,196
Accrued Legal Expenses	116,578	181,597
Accrued Marketing Expenses	191,797	61,164
Other Accrued Liabilities	1,827,377	2,973,368
Total Accrued Liabilities	$ 4,437,080	$ 4,517,732

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Jan. 14, 2020	Oct. 31, 2014	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2016	Dec. 31, 2019
Deferred Revenue Arrangement [Line Items]
Deferred revenue			$ 11,084,000		$ 11,084,000			$ 12,076,000
Baxter Healthcare Organization
Deferred Revenue Arrangement [Line Items]
Upfront payment		$ 20,000,000
Recognized deferred revenue			500,000	$ 1,000,000	500,000	$ 100,000
Deferred revenue			8,200,000		$ 8,200,000			9,100,000
Refund eligible for, percent of upfront fee					25.00%
Partial refund					$ 5,000,000
Wanbang Biopharmaceutical
Deferred Revenue Arrangement [Line Items]
Upfront payment							$ 4,000,000
Recognized deferred revenue			53,000	$ 100,000	53,000	$ 100,000
Deferred revenue			2,900,000		2,900,000			$ 3,000,000
Sun Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment	$ 100,000
Recognized deferred revenue			$ 2,500		$ 5,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	Feb. 21, 2020	Feb. 06, 2020	Mar. 22, 2019	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	May 18, 2020	Feb. 19, 2020	Feb. 04, 2020
Class of Stock [Line Items]
Increase in common stock issuable (in shares)								2,900,000
Preferred stock, authorized (in shares)					2,000,000		2,000,000
Preferred shares, par value (in dollars per share)					$ 0.0001		$ 0.0001
Preferred shares, shares issued (in shares)					0		0
Preferred shares, shares outstanding (in shares)					0		0
Common shares, shares authorized (in shares)					170,000,000		170,000,000
Common shares, par value (in dollars per share)					$ 0.0001		$ 0.0001
Common Shares, shares issued (in shares)					70,156,922		65,378,890
Common Shares, shares outstanding (in shares)					70,156,922		65,378,890
Issuance of common stock (in shares)					987,716		1,840,443
Proceeds from the issuance of common shares				$ 8,000,000	$ 2,034,073		$ 5,383,079
Weighted average selling price (in dollars per share)					$ 2.06		$ 2.92
Common share issuance costs					$ 56,443		$ 309,479
Remaining amount available for sale					32,600,000
Maximum
Class of Stock [Line Items]
Sales agreement, threshold sale of shares			$ 40,000,000
Public offering
Class of Stock [Line Items]
Issuance of common stock (in shares)		3,191,489
Proceeds from the issuance of common shares	$ 8,000,000				8,147,871	$ 17,500,002
Common share issuance costs	$ 100,000				$ 143,914	$ 1,379,323
Common stock reserved for future issuance (up to) (in shares)										3,670,212
Share price (in dollars per share)		$ 2.22							$ 2.22
Over allotment
Class of Stock [Line Items]
Common stock reserved for future issuance (up to) (in shares)									478,723	478,723

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ (1,461,014)	$ 1,501,326	$ (526,168)	$ 3,018,628
Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	332,386	974,611	1,010,125	1,970,986
Restricted stock units - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	(4,127)	427,472	233,987	771,823
Stock option awards - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	336,513	547,139	776,138	1,199,163
Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	(1,793,400)	526,715	(1,536,293)	1,047,642
Restricted stock units - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	(1,196,713)	402,814	(1,025,502)	801,202
Stock option awards - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ (596,687)	$ 123,901	$ (510,791)	$ 246,440

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Unvested restricted stock awards
Number of Shares
Unvested, Number of Shares (in shares)	146,800	146,800	146,800	146,800
Weighted Average Grant Date Fair Value
Unvested, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 5.70	$ 5.70	$ 5.70	$ 5.70
Vesting period	20 months
Restricted stock awards - Performance based
Number of Shares
Unvested, Number of Shares (in shares)	146,800

Stock-Based Compensation - Serv

Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)	Apr. 17, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Weighted Average Grant Date Fair Value
Stock based compensation expenses		$ (1,461,014)	$ 1,501,326	$ (526,168)	$ 3,018,628
Restricted stock units - Service based awards
Number of Shares
Unvested at beginning of period (in shares)				463,786	472,959
Granted (in shares)				188,904	199,938
Vested (in shares)				(128,460)
Forfeited (in shares)				(104,168)	(3,650)
Unvested at end of period (in shares)		420,062	669,247	420,062	669,247
Weighted Average Grant Date Fair Value
Unvested at beginning of period (in dollars per share)				$ 4.26	$ 4.32
Granted (in dollars per share)				2.09	4.45
Vested (in dollars per share)				4.30
Forfeited (in dollars per share)				4.66	4.81
Unvested at end of period (in dollars per share)		$ 3.27	$ 4.36	$ 3.27	$ 4.36
Stock based compensation expenses		$ (4,127)	$ 427,472	$ 233,987	$ 771,823
Unrecognized stock-based compensation expense		$ 600,000		$ 600,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)				1 year
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 200,000
Minimum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period				1 year
Maximum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period				3 years
President and Chief Executive Officer | Restricted stock units - Service based awards
Number of Shares
Forfeited (in shares)					(96,541)

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Restricted Stock Units (Details) - USD ($)	Apr. 17, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Fair value assumptions:
Stock based compensation expenses		$ (1,461,014)	$ 1,501,326	$ (526,168)	$ 3,018,628
Restricted stock units - Performance based awards
Number of Shares
Unvested at beginning of period (in shares)				988,958	988,958
Forfeited (in shares)				(905,625)
Unvested at end of period (in shares)		83,333	988,958	83,333	988,958
Weighted Average Grant Date Fair Value
Unvested at beginning of period (in dollars per share)				$ 4.48	$ 4.48
Forfeited (in dollars per share)				4.61
Unvested at end of period (in dollars per share)		$ 3.09	$ 4.48	$ 3.09	$ 4.48
Fair value assumptions:
Stock based compensation expenses		$ (1,196,713)	$ 402,814	$ (1,025,502)	$ 801,202
Unrecognized stock-based compensation expense		$ 100,000		$ 100,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)				2 years
President and Chief Executive Officer | Restricted stock units - Performance based awards
Number of Shares
Forfeited (in shares)	(905,625)
Fair value assumptions:
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 1,300,000

Stock-Based Compensation - Se_2

Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details) - Stock option awards - Service based awards	6 Months Ended
	Jun. 30, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility, minimum	68.20%
Expected stock price volatility, maximum	74.40%
Risk-free interest rate, minimum	0.35%
Risk-free interest rate,maximum	1.65%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1.77
Term (years)	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 2.45
Term (years)	6 years 6 months

Stock-Based Compensation - Se_3

Stock-Based Compensation - Service Based Stock Options (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Exercise Price
Exercised (in dollars per share)	$ 2.06		$ 2.92
Stock option awards - Service based awards
Shares Underlying Options
Outstanding at the beginning of the period (in shares)	8,210,024	7,856,480	7,856,480
Granted (in shares)	1,610,344	523,105
Exercised (in shares)		(30,000)
Forfeited (in shares)	(211,471)	(550,549)
Expirations (in shares)	(3,983,335)
Outstanding at the end of the period (in shares)	5,625,562	7,799,036	8,210,024	7,856,480
Exercisable at end of period (in shares)	2,809,954	6,183,193
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 7.06	$ 7.50	$ 7.50
Granted (in dollars per share)	2.24	4.33
Exercised (in dollars per share)		4.93
Forfeited (in dollars per share)	4.41	6.67
Expirations (in dollar per share)	8.30
Outstanding at the end of the period (in dollars per share)	4.90	7.36	$ 7.06	$ 7.50
Exercisable (in dollars per share)	$ 7.09	$ 8.16
Weighted Average Remaining Contractual Term
Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 12 days	5 years 4 months 24 days	5 years 1 month 6 days	5 years 2 months 12 days
Granted, Weighted Average Remaining Contractual Term	5 years 10 months 24 days	9 years 8 months 12 days
Exercisable, Weighted Average Remaining Contractual Term	4 years 3 months 18 days	4 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 1,100	$ 2,500	$ 107,150	$ 0
Intrinsic Value	$ 0	$ 0

Stock-Based Compensation - Se_4

Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)	Apr. 17, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expenses		$ (1,461,014)	$ 1,501,326	$ (526,168)	$ 3,018,628
Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)				211,471	550,549
Stock based compensation expenses		336,513	$ 547,139	$ 776,138	$ 1,199,163
Unrecognized stock-based compensation expenses		$ 3,100,000		$ 3,100,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)				1 year 4 months 24 days
Expirations (in shares)				3,983,335
Employee stock options | Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				1,610,344
President and Chief Executive Officer | Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)	129,375
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 200,000
Chief Executive Officer and Chief Financial Officer | Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expirations (in shares)				3,783,335

Stock-Based Compensation - Pe_2

Stock-Based Compensation - Performance Based Stock Options (Details) - USD ($)	Apr. 17, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Weighted Average Exercise Price
Stock based compensation expenses		$ (1,461,014)	$ 1,501,326	$ (526,168)	$ 3,018,628
Stock option awards - Performance based awards
Number of Shares
Outstanding at the beginning of the period (in shares)				388,125	388,125
Granted (in shares)				600,000
Forfeited (in shares)				(388,125)
Outstanding at the end of the period (in shares)		600,000	388,125	600,000	388,125
Exercisable at end of period (in shares)		0	0	0	0
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)				$ 4.70	$ 4.70
Granted (in dollars per share)				2.45
Forfeited (in dollars per share)				4.70
Outstanding at the end of the period (in dollars per share)		$ 2.45	$ 4.70	2.45	4.70
Exercisable (in dollars per share)		$ 0	$ 0	$ 0	$ 0
Stock based compensation expenses		$ (596,687)	$ 123,901	$ (510,791)	$ 246,440
Unrecognized stock-based compensation expenses		$ 100,000		$ 100,000
President and Chief Executive Officer | Stock option awards - Performance based awards
Number of Shares
Forfeited (in shares)	(388,125)
Weighted Average Exercise Price
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 700,000

Related Party Transactions (Det

Related Party Transactions (Details)	Oct. 07, 2018USD ($)agreementinstallment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2020USD ($)	Jul. 15, 2019USD ($)	Apr. 15, 2019USD ($)	Jan. 15, 2019USD ($)	Oct. 15, 2018USD ($)
Related Party Transaction [Line Items]
Number of additional agreements | agreement	3
Product development and research costs			$ 1,100,000
Related party transactions, accrued reimbursement of IP expenses				$ 200,000
Master services and IP agreements
Related Party Transaction [Line Items]
Payments to acquire assets			$ 1,100,000
Milestone payments				0
Executive Vice President and Chief Scientific Officer
Related Party Transaction [Line Items]
Total amount due	$ 1,000,000	$ 100,000		$ 27,500	$ 250,000	$ 250,000	$ 250,000	$ 250,000
Number of quarterly installment payments | installment	4
Installment paid		1,000,000
Related party transactions, accrued reimbursement of legal expenses		$ 100,000

Leases - Narrative (Details)

Leases - Narrative (Details)	Jun. 30, 2020USD ($)ft²	Dec. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Operating lease liabilities | $	$ 2,546,438
Operating lease, right of use assets | $	$ 2,440,115	$ 3,212,530
Grapevine, Texas
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Hackensack, New Jersey
Lessee, Lease, Description [Line Items]
Facility sqft.	4,100
Lease facility one | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Lease facility one | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	57,000
Lease facility two | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	17,500
Lease facility two | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	1,408
Maximum
Lessee, Lease, Description [Line Items]
Lease term	5 years

Leases - Summary of Operating L

Leases - Summary of Operating Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 403,077	$ 554,921	$ 845,905	$ 1,089,888
Variable lease cost	122,865	78,237	312,149	168,081
Operating lease expense	525,942	633,158	1,158,054	1,257,969
Short-term lease rent expense	4,157	4,122	8,313	8,313
Total rent expense	530,099	637,280	1,166,367	1,266,282
Operating cash flows from operating leases	410,092	514,116	854,785	1,038,081
Right of use assets exchanged for operating lease liabilities	$ 0	$ 821,195	$ 0	$ 4,305,428
Weighted-average remaining lease term – operating leases	2 years 4 months 24 days	2 years 7 months 6 days	2 years 4 months 24 days	2 years 7 months 6 days
Weighted-average discount rate – operating leases	6.80%	6.80%	6.80%	6.80%

Leases - Future Minimum Rental

Leases - Future Minimum Rental Payments Under Operating Leases (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
Year ending December 31, 2020 (remaining)	$ 780,038
Year ending December 31, 2021	1,054,873
Year ending December 31, 2022	591,925
Year ending December 31, 2023	234,327
Year ending December 31, 2024	97,423
Total	2,758,586
Less present value discount	(212,148)
Operating lease liabilities	$ 2,546,438

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jul. 31, 2020	Aug. 07, 2019	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Loss Contingencies [Line Items]
Amount of penalties sought from supplier			$ 3,000,000
Settlement expense				$ 0	$ 430,000		$ 0	$ 430,000	$ 400,000
Settlement agreement with all parties
Loss Contingencies [Line Items]
Litigation settlement amount		$ 3,700,000
Settlement expense							$ 100,000
Subsequent Event
Loss Contingencies [Line Items]
Percentage of raw materials to be paid	50.00%
Forecast
Loss Contingencies [Line Items]
Percentage of raw materials to be paid						50.00%

Loans and Security Agreement -

Loans and Security Agreement - Narrative (Details)	Mar. 16, 2020USD ($)day$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Debt Instrument [Line Items]
Net draw down proceeds	$ 21,200,000
Term Loan | Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 35,000,000
Interest rate, base percentage	4.75%
Interest rate, additional percentage added to base percentage	4.00%
Initial interest rate percentage	8.75%
Effective interest rate	10.90%
Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage	1.00%
Interest expense		$ 500,000	$ 0	$ 600,000	$ 0
Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant Term Loan funded funded	3.50%
Warrant exercise price calculation, period immediately preceding execution of Loan Agreement, number of trading days | day	5
Outstanding balance, net of unamortized issuance costs and unaccreted discount		20,800,000		20,800,000
Unamortized issuance costs and unaccreted discount		$ 1,700,000		$ 1,700,000
Term Loan | Term Loan | Minimum
Debt Instrument [Line Items]
Period for which Company is entitled to make interest-only payments	30 months
Term Loan | Term Loan | Maximum
Debt Instrument [Line Items]
Period for which Company is entitled to make interest-only payments	36 months
Term Loan | Term Loan, First Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 22,500,000
Net draw down proceeds	21,200,000
Closing costs	$ 1,300,000
Exercise price of warrant (in dollars per share)) | $ / shares	$ 1.65
Number of shares of common stock for which warrant is exercisable (in shares) | shares	477,273
Term Loan | Term Loan, Second and Third Tranches
Debt Instrument [Line Items]
Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days | day	5
Term Loan | Term Loan, Second and Third Tranches | Maximum
Debt Instrument [Line Items]
Exercise price of warrant (in dollars per share)) | $ / shares	$ 1.65
Term Loan | Term Loan, Second Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 5,000,000
Term Loan | Term Loan, Third Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 7,500,000

Loans and Security Agreement _2

Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term Loan - Term Loan	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
2020	$ 0
2021	0
2022	2,250,000
2023	9,000,000
2024	9,000,000
2025	2,250,000
Principal Payments	$ 22,500,000

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Jul. 03, 2020USD ($)
Subsequent Event | Chief Financial Officer
Subsequent Event [Line Items]
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 0.7